Weak sensitisation of low dose GC therapy response by mir-150-5p mimetic transfection can be reversed by transfection of a mir-150-5p-specific antagomir in MM1S cells.

<p>(<b>A</b>) MTT based quantification of MM1S cell survival, following 24, 48, or 72 h transfection with increasing doses of synthetic mir-150-5p mimetic as compared to mock transfection control (<b>B</b>) MTT based quantification of MM1S cell survival, following 72 h treatment with increasing doses of Dex, in combination with either mock transfection, else transfection with a synthetic mir-150-5p mimetic or mir-150-5p specific antagomir (as indicated in figure). Data represented are relative cell survival levels (mean ± SEM) of three independent experiments. Means with ***, **, * are significantly different (p<0.001, <0.01 or <0.05) from control setup as determined by two-way ANOVA (Bonferroni posttests). (<b>C</b>) Realtime quantitative PCR (QPCR) quantification of mir-150-5p transcription levels following 72 h treatment with 1 nM Dex, either or not in combination with transfection of a mir-150-5p specific antagomir. (<b>D–E</b>) Illumina BeadChip Gene Expression results of a subset of genes are presented as bargraphs, reflecting the mean fold change from three independent experiments of MM1S cells treated for 72 h with 1 nM Dex vs. control setup, either or not in combination with transfection of a mir-150-5p specific antagomir.